Actuate Therapeutics Common Stock Market Value
| ACTU Stock | 5.52 0.23 4.00% |
| Symbol | Actuate |
Actuate Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actuate Therapeutics. If investors know Actuate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actuate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Actuate Therapeutics is measured differently than its book value, which is the value of Actuate that is recorded on the company's balance sheet. Investors also form their own opinion of Actuate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Actuate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actuate Therapeutics' market value can be influenced by many factors that don't directly affect Actuate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actuate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actuate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actuate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Actuate Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Actuate Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Actuate Therapeutics.
| 01/26/2024 |
| 01/15/2026 |
If you would invest 0.00 in Actuate Therapeutics on January 26, 2024 and sell it all today you would earn a total of 0.00 from holding Actuate Therapeutics Common or generate 0.0% return on investment in Actuate Therapeutics over 720 days. Actuate Therapeutics is related to or competes with Seres Therapeutics, Spero Therapeutics, VistaGen Therapeutics, Elicio Therapeutics, Nkarta, Vor Biopharma, and Alector. Actuate Therapeutics is entity of United States More
Actuate Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Actuate Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Actuate Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 20.01 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 5.05 |
Actuate Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Actuate Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Actuate Therapeutics' standard deviation. In reality, there are many statistical measures that can use Actuate Therapeutics historical prices to predict the future Actuate Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (1.10) | |||
| Treynor Ratio | (2.18) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Actuate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Actuate Therapeutics Backtested Returns
Actuate Therapeutics secures Sharpe Ratio (or Efficiency) of -0.11, which signifies that the company had a -0.11 % return per unit of risk over the last 3 months. Actuate Therapeutics Common exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Actuate Therapeutics' Standard Deviation of 3.75, risk adjusted performance of (0.09), and Mean Deviation of 2.79 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.24, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Actuate Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Actuate Therapeutics is expected to be smaller as well. At this point, Actuate Therapeutics has a negative expected return of -0.43%. Please make sure to confirm Actuate Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Actuate Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.29 |
Poor predictability
Actuate Therapeutics Common has poor predictability. Overlapping area represents the amount of predictability between Actuate Therapeutics time series from 26th of January 2024 to 20th of January 2025 and 20th of January 2025 to 15th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Actuate Therapeutics price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current Actuate Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | 0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 1.74 |
Actuate Therapeutics lagged returns against current returns
Autocorrelation, which is Actuate Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Actuate Therapeutics' stock expected returns. We can calculate the autocorrelation of Actuate Therapeutics returns to help us make a trade decision. For example, suppose you find that Actuate Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Actuate Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Actuate Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Actuate Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Actuate Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Actuate Therapeutics Lagged Returns
When evaluating Actuate Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Actuate Therapeutics stock have on its future price. Actuate Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Actuate Therapeutics autocorrelation shows the relationship between Actuate Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Actuate Therapeutics Common.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.